Komsan Loonprom / Shutterstock.com
24 October 2024NewsAmericasLiz Hockley
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
24 September 2024 Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.
Editor's picks
Editor's picks
Americas
24 September 2024 Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.
Americas
24 September 2024 Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.